World's First Phase III Inactivated Covid-19 Jab Tests Forge Ahead as Data Surprises
Zhang Yushuo
DATE:  Nov 12 2020
/ SOURCE:  Yicai
World's First Phase III Inactivated Covid-19 Jab Tests Forge Ahead as Data Surprises World's First Phase III Inactivated Covid-19 Jab Tests Forge Ahead as Data Surprises

(Yicai Global) Nov. 12 -- The Phase III clinical trials of the world's first inactivated Covid-19 vaccine to win approval are going smoothly and entering the home stretch with all data better than expected, its developer China National Biotec Group under China National Pharmaceutical Group -- better known as Sinopharm -- announced on its WeChat account yesterday.

The trials underway in the UAE, Bahrain, Egypt, Jordan, Morocco, Peru and Argentina that have already inoculated over 50,000 volunteers have now amassed samples spanning 125 nationalities.

This vaccine gained the world's first clinical trial authorization from the National Medical Products Administration of China on April 12. Beijing-based Sinopharm and CNBG will promote its research and development in strict accordance with applicable procedures and ensure its safety by not skipping any steps, Sinopharm pledged.

National governments have strongly supported and fully affirmed the Phase III clinical trials CNBG has carried out in various countries. Many local politicians who have taken the lead in getting a shot have voiced their confidence in the safety and effectiveness of the CNBG-developed jab and its testing, per the announcement.

The UAE and Bahrain authorized emergency use of the new coronavirus jab for frontline health workers, teachers, police and customs officers, Gulf News reported on Sept. 15.

More than 51 million global Covid-19 cases had been diagnosed by yesterday as the grim specter of a second wave of the pestilence that has already claimed over 1 million lives looms throughout the globe.

Editor: Ben Armour, Xiao Yi
 

Follow Yicai Global on
Keywords:   Covid-19,National Pharmaceutical Group,Sinopharm,vaccine